

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/517,869
Filing Date	October 12, 2005
First Named Inventor	Anders Lehmann
Art Unit	1614
Examiner Name	Spivack, Phyllis G.
Attorney Docket Number	1103326-0946

Sheet	1	of	1
-------	---	----	---

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Patentee AstraZeneca's response, dated 25 June 2009, to the Opposition against EP 1 513 525 B1 filed by Addex Pharma S.A. and separately by Novartis AG.	
		The EPO's preliminary and non-binding opinion dated 19 October 2009 with regard to the Opposition against EP 1 513 525 B1.	
		Supplemental submission, dated 28 July 2010, by the opponent Novartis AG in its Opposition against EP 1 513 525 B1.	
		Trilateral Project B3b: Mutual understanding in search and examination: Report on comparative study on biotechnology patent practices: Theme – comparative study on “reach-through claims”, EPO, JPO, USPTO, November 5-9, 2001.	
Examiner Signature		Date Considered	

[illegible]